Opdivo Improves Survival in Advanced Esophageal Cancer: ATTRACTION-3 Trial
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On September 30, 2019, clinical results were announced for the ATTRACTION-3 Phase 3 clinical trial, evaluating the anti-PD-1 antibody Opdivo (Nivolumab) in patients with unresectable advanced or recurrent esophageal cancer who were refractory to or intolerant of fluoropyrimidine- and platinum-based chemotherapy.
Study Design: ATTRACTION-3 Trial
This international, multicenter, open-label trial randomized patients into two groups:
- Opdivo Group: Nivolumab monotherapy.
- Chemotherapy Group: Investigator's choice of Taxotere (docetaxel) or Paclitaxel.
The primary endpoint was overall survival (OS).
Key Survival Results
The trial demonstrated a significant survival benefit for Opdivo:
- Median Overall Survival: 10.9 months for Opdivo vs. 8.4 months for chemotherapy.
- Risk Reduction: Opdivo reduced the risk of death by 23% (Hazard Ratio [HR] = 0.77).
- 12-Month OS Rate: 47% (Opdivo) vs. 31% (Chemotherapy).
- 18-Month OS Rate: 31% (Opdivo) vs. 21% (Chemotherapy).
Importantly, the survival benefit of Opdivo was observed regardless of the patient's PD-L1 expression levels.
Efficacy and Safety
- Objective Response Rate (ORR): 19% for Opdivo vs. 22% for chemotherapy.
- Duration of Response: Significantly longer with Opdivo (6.9 months) compared to chemotherapy (3.9 months).
- Safety: Opdivo was better tolerated, with a Grade 3/4 adverse event rate of 18% compared to 63% in the chemotherapy group.
Conclusion
Dr. Byoung Chul Cho and colleagues concluded that Opdivo significantly improves overall survival compared to standard chemotherapy in patients with previously treated advanced esophageal cancer, with a more favorable safety profile. These results support Opdivo as a new second-line standard of care for this population.
Source: BMS Press Release - ATTRACTION-3 Trial Results
#EsophagealCancer #Opdivo #Nivolumab #ATTRACTION3 #Immunotherapy #CancerResearch
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4